article thumbnail

Innovative Approaches to Generic Drug Development: Case Studies

Drug Patent Watch

.”[2] This study not only addressed the ATA’s concerns but also highlighted the power of real-world evidence in generic drug development and regulation. Case Study 3: Modeling the Future of Generic Drugs Who says you need a crystal ball to predict the future? Language on the label regarding patient weight gain.

article thumbnail

STAT+: Pharmalittle: FTC may sue to block Amgen deal for Horizon; Supreme Court declines Teva appeal on skinny labeling

STAT

billion deal would hamper innovation and slow the pace of drug development. Federal Trade Commission is expected to file a lawsuit to block Amgen from acquiring Horizon Therapeutics, Bloomberg News writes. The agency will argue that the $27.8

Labelling 230
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Animal rights group urges SEC to investigate Charles River over monkey purchases

STAT

And Charles River was also accused of falsely labeling the monkeys in sales made to its research clients. The company, one of the largest clinical research organizations, was accused of failing to disclose purchases of thousands of non-human primates that should not have been imported into the U.S.

Labelling 351
article thumbnail

The biotech news you need to read today

STAT

Today we take note of the antagonism between gene-editing players Prime Medicine and Tessera Therapeutics, consider the issue of whether the label should be updated on a Merck drug, and more.   Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox. 

Labelling 260
article thumbnail

Contineum Therapeutics files for IPO

STAT

Today we ponder the vast open spaces of Boston’s unused life sciences labs, see a new biopharma IPO in the works, and expect a label expansion for some CAR-T blood cancer therapies.   Sign up  to get our biotech newsletter in your inbox. Read the rest…

Labelling 280
article thumbnail

Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

Express Pharma

This study consists of a 36-week treatment phase, followed by a 16-week open-label extension. 1162 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Three Patients with Cryopyrin-Associated Periodic Syndromes, Clinical Pharmacology in Drug Development, 2023, 0(0) 18. DOI: 10.1002/cpdd.1162

article thumbnail

STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity

STAT

  Mounjaro, known scientifically as tirzepatide, is one of an emerging class of drugs that target receptors of the GLP-1 hormone, and sometimes other molecules, and that have had dramatic effects on weight loss. Continue to STAT+ to read the full story…

Diabetes 308